A prospective 10‐year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease
Raphael Schiffmann(Texas Christian University), Markus Ries(Heidelberg University), Caren Swift, Derek Blankenship(Renal Research Institute), Xuan Wang(Tongji University)
Cited by 38
Related Papers
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis
|Molecular Cancer|2020|465
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
|Nephrology Dialysis Transplantation|2009|366
Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies
|Neuroscience & Biobehavioral Reviews|2022|151